CT-996
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About CT-996
CT-996 is Structure Therapeutics' oral small-molecule GLP-1 receptor agonist in early clinical development, designed for once-daily oral dosing with minimal food restrictions. Phase Ib data showed up to 6% weight loss over 28 days, promising for an early-stage program. It competes in the oral GLP-1 space with orforglipron and danuglipron, differentiated by its distinct chemical scaffold and once-daily convenience.
Science
Mechanism of Action
Non-peptide small molecule GLP-1 receptor agonist acting on both central (hypothalamic appetite regulation) and peripheral (pancreatic insulin secretion, gastric motility) GLP-1 receptor populations through oral bioavailable formulation.
Dosing
Typical Protocol
Oral once-daily dosing; Phase Ib doses and titration schedule under clinical investigation.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
CT-996 is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.